# Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

> **NCT05313022** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Zerun Biotechnology Co.,Ltd** · enrollment: 84 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** ZR-202-CoV
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05313022
- **Lead sponsor:** Shanghai Zerun Biotechnology Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-18
- **Primary completion:** 2022-05-13
- **Final completion:** 2023-06
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2023-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05313022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05313022, "Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05313022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*